MYSTIC, Conn. and DUBLIN, Jan. 6, 2011 /PRNewswire/ — Amarin
Corporation plc (Nasdaq:
AMRN) (the “Company”), a clinical-stage biopharmaceutical
company with a focus on cardiovascular disease, today announced the
pricing of an underwritten public offering of 12,000,000 American
Depositary Shares (“ADSs”) at a price to the public of $7.60 per
ADS. The net proceeds to the Company from this offering are
expected to be approximately $87.1 million, after deducting
underwriting discounts and commissions and other estimated offering
expenses. The offering is expected to close on or about January 11,
2011, subject to customary closing conditions.
Jefferies & Company, Inc. and Leerink Swann LLC are acting
as joint book-running managers in the offering, and Canaccord
Genuity Inc. is acting as co-lead manager for the offering. Amarin
has granted the underwriters a 30-day option to purchase up to an
aggregate of 1,800,000 additional ADSs solely to cover
over-allotments, if any. Amarin anticipates using the net proceeds
from the offering to prepare for the commercialization of AMR101,
its filing of a New Drug Application and for working capital and
general corporate purposes.
The securities described above are being offered by Amarin
pursuant to a shelf registration statement previously filed with
and declared effective by the Securities and Exchange Commission
(the “SEC”) on November 23, 2010. A preliminary prospectus
supplement related to the offering has been filed with the SEC and
is available on the SEC’s website at http://www.sec.gov.
Copies of the final prospectus supplement relating to these
securities may be obtained from Equity Syndicate Prospectus
Department, Jefferies & Company, Inc., 520 Madison Avenue,
12th Floor, New York, NY, 10022, at 877-547-6340, and at
Prosp
‘/>”/>
